Home›Trial›NCT05130255
🔬NCT05130255Phase 1RECRUITING

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Study Summary

Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability

Conditions
SCLCMalignant MelanomaSarcomaHigh Risk Neuroblastoma
Interventions / Drugs
GD2-SADA:177Lu-DOTA Complex
View on ClinicalTrials.gov ↗
Sponsor
YMAB
Y-mAbs Therapeutics
Pediatric Oncology
D40/100
Study Details
Enrollment60 participants
Primary Completion—
Lead SponsorY-mAbs Therapeutics
Data Retrieved2026-04-11 04:32:06.541543+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.